Gensight Biologics S.a annual diluted eps
Diluted EPSBasic EPS
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a EPS History: Annual & Quarterly (SIGHT)
Gensight Biologics S.a's diluted EPS was -€0.08 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -€0.08 | -€0.08 | €0.07 | — |
| 2024 | 2024-12-31 | -€0.15 | -€0.15 | €0.39 | — |
| 2023 | 2023-12-31 | -€0.54 | -€0.54 | €0.06 | — |
| 2022 | 2022-12-31 | -€0.60 | -€0.60 | €0.03 | — |
| 2021 | 2021-12-31 | -€0.63 | -€0.63 | €0.34 | — |
| 2020 | 2020-12-31 | -€0.97 | -€0.97 | — | — |
Gensight Biologics S.a diluted eps trends
Over the last five fiscal years, Gensight Biologics S.a's diluted eps increased from -€0.97 to -€0.08, a change of €0.89.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from official filings. Historical EPS values are adjusted to the current share basis when reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...